Metabolic syndrome secondary prevention

Jump to navigation Jump to search

Metabolic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Metabolic Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Dietary Therapy

Physical Activity

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Metabolic syndrome secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Metabolic syndrome secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Metabolic syndrome secondary prevention

CDC on Metabolic syndrome secondary prevention

Metabolic syndrome secondary prevention in the news

Blogs on Metabolic syndrome secondary prevention

Directions to Hospitals Treating Metabolic syndrome

Risk calculators and risk factors for Metabolic syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Effective measures for the secondary prevention of metabolic syndrome, in order to prevent its complication, are included monitoring lipid levels every 6 weeks, serum aminotransferase and CK levels every 6 months. Blood pressure, blood glucose, and HbA1c should be checked every 3 months.

Secondary Prevention

Effective measures for the secondary prevention of metabolic syndrome, in order to prevent its complication, are included:

  • Monitoring lipid levels every 6 weeks until target levels are achieved and, once stable, every 6 months.
  • Serum aminotransferase and CK levels should be measured before initiating statins, fibrates, ezetimibe, or niacin. They should be rechecked each time the medication dose is adjusted and monitored every 6 months once the dose is stable.
  • Blood pressure, blood glucose, and HbA1c should be checked every 3 months.
  • Waist circumference and BMI should be measured every month.

References

Template:WS Template:WH